Go to Page # Page of 27

Pharma Needs: Go No-Go Decisions in Therapeutic Drug Development

 Diane Jorkasky, MD, FACP
Description: Worst year in history for Pharma: – Rising R&D Costs – Declining productivity…… declining creativity? – Uncertain pipelines – big risks, exceptional failures – Increasing regulatory conservatism – Financial instability impacting all investment – Conflict of interest impacts and yet… …..no more important time for academia and industry to work together – to develop new therapeutic agents. Should we embark on this biological target? What are Pharma’s needs in therapeutic drug development?
Views: 3484
Domain: Medical
Category: Biotech/Pharma
Pharma needs: Go No-Go Decisions in Therapeutic Drug Development
Diane Jorkasky, MD, FACP Independent Consultant (Retired from Pfizer Global Research & Development) February 8, 2009 Society of Nuclear Medicine


Why am I here?
� � � nephrologist, clinical pharmacology early development x 23 years former chair, Yale / Pfizer Imaging Alliance in PET technology ... See more

Recent Presentations

FDA Approach to the Opioids Crisis

Opioid Crisis is not one crisis, but multiple challenges to prescribers, patients & healthcare system. FDA is working in a prioritized way in multiple areas to confront opioid over

18 April, 2019
Ralph F. Hall
17 April, 2019

Investment Trends in Healthcare

Macroeconomic drivers are leading to an unprecedented healthcare industry change. Healthcare is one of the most impacted industry by technology breakthrough.

Danilo Mazzara
16 April, 2019